Abstract:Prediction of rectal cancer response to preoperative chemo-radiation therapy (CRT) provides the opportunity to perform individualized therapy. 18-Fluorine fluorodeoxyglucose positron emission tomography (18F-FDG PET), which can reflect intrinsic biological activity within tumor, is a promising tool for monitoring the effect of anti-tumor therapy. The aim of this study was to investigate the potential of sequential PET/CT in assessing and predicting of histopathological response to preoperative CRT of rectal cancer. 28 patients with T3-4 and/or N+ rectal cancer were enrolled between Jun 2009 and Dec 2010. All patients received preoperative CRT (pelvic radiation therapy: 50-55Gy/25Fx; concurrent chemotherapy using capecitabine and oxaliplatin) followed by radical surgery after 6-8 weeks. All patients underwent baseline 18F-FDG PET/CT scans within 1 week prior to the initiation of treatment (PET/CT1) and a second scan within 1 week after the completion of CRT (PET/CT2). 18 of the 28 patients also underwent a third PET/CT within 1 week prior to the surgery (PET/CT3). SUVmax, SUVmean, metabolic tumor volume (MV) and total lesion glycolysis (TLG, MV×SUVmean) were measured in each PET/CT imaging. Response indices (RI: percentage differences among PET/CT1, 2 and 3) of SUV, MV and TLG were calculated. The different metabolic parameters were analyzed and correlated with pathological treatment response. When patients were classified as pathological complete response (pCR) and non-pCR, significant differences in RI-MV(1-3) (59.86% vs. 84.79%, P = 0.005), RI-TLG(1-3) (73.46% vs. 91.45%, P = 0.007), RI-SUVmax(2-3) (-0.99% vs. 36.1%, P = 0.021) were observed between the two groups. When patients were classified into three groups (Group1: no residual tumor cells, pCR; Group2: rare residual tumor cells; Group3: others), significant differences in RI-MV(1-3) and RI-TLG(1-3) were also observed. RI-MV(1-3) ,RI-TLG(1-3) and RI-SUVmax(2-3) were significantly lower in Group1 than in Group2 (59.86% vs. 85.95%, P = 0.027; 73.46% vs. 91.71%, P = 0.027; -0.99% vs. 38.83%, P = 0.027). RI-MV(1-3) and RI-TLG(1-3) were also significantly lower in Group1 than in Group3 (59.86% vs. 84.28%, P = 0.009; 73.46% vs. 91.33%, P = 0.014) while RI-SUVmax(2-3) showed lower trend in Group1 than in Group3(-0.99% vs. 34.89%, P = 0.053). However, significant differences in these parameters were not observed between Group2 and Group3. The variation of 18F-FDG PET/CT has the potential of evaluating and predicting of preoperative CRT response in rectal cancer especially SUV combined with metabolic area volume. However, the utility of PET/CT to guide treatment decisions should be further explored in larger clinical studies.

F-18-Fdg Pet/Ct Metabolic Parameters And Her2 Expression In Colorectal Cancer

18F-FDG PET/CT Metabolic Parameters and HER2 Expression in Colorectal Cancer

18F-FDG PET/CT for the Early Prediction of the Response Rate and Survival of Patients with Recurrent or Metastatic Breast Cancer.

18F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor

The preoperative SUVmax for 18 F-FDG uptake predicts survival in patients with colorectal cancer

The Correlation between 18F-FDG PET/CT Imaging SUVmax of Preoperative Colon Cancer Primary Lesions and Clinicopathological Factors

Exploring the correlation between HER2 alterations and 18 F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients

Exploring the correlation between HER2 alterations and 18F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients

F-18-Fdg Pet/Ct Can Predict Chemosensitivity And Proliferation Of Epithelial Ovarian Cancer Via Suvmax Value

Relation Between Metabolic Parameters of 18F-FDG PET/CT and Clinicopathological Features of Colorectal Cancer Patients

Evaluation of prognostic risk factors of triple-negative breast cancer with 18F-FDG PET/CT parameters, clinical pathological features and biochemical indicators

Value of pretreatment 18F-FDG PET/CT uptake heterogeneity for early prediction of response to targeted therapy in patients with HER2 positive metastatic breast cancer

Prediction of HER2 Expression in Gastric Adenocarcinoma Based On Preoperative Noninvasive Multimodal 18F-FDG PET/CT Imaging

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.

The Role of 18F-FDG PET/CT in Predicting Tumor Response after Preoperative Chemo-radiation Therapy for Rectal Cancer

Prediction value of 18F-FDG PET/CT intratumor metabolic heterogeneity parameters for recurrence after radical surgery of stage II/III colorectal cancer

Volumetric parameters on 18 F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET

A Preliminary Study of 18F-FES PET/CT in Predicting Metastatic Breast Cancer in Patients Receiving Docetaxel or Fulvestrant with Docetaxel

Predictive Value of Metabolic Parameters Derived From 18F-FDG PET/CT for Microsatellite Instability in Patients With Colorectal Carcinoma

An Investigation of the Relationship Between 18F-FDG PET/CT Parameters of Primary Tumors and Lymph Node Metastasis in Resectable Non-small Cell Lung Cancer

18 F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value